Germany’s six-month gate: 82% of reimbursed cannabis at risk — and who stands to gain
On 10 July 2026 the Bundestag reshaped Germany’s reimbursed medical cannabis market — striking dried flower from statutory cover and gating extracts, dronabinol and nabilone behind a six-month trial of an approved finished medicine. On our figures that puts roughly €205 million — about 82% of a €248.8 million market — in play. This is […]
Inside Swiss medical cannabis: maturing beyond oils and pain — but who pays?
Switzerland’s 2022 reform made medical cannabis legally accessible to any prescriber, yet two years of federal MeCanna data reveal a market still defined by limited scale rather than open access. Beneath that constrained surface the picture is shifting: a patient base broadening beyond pain, and a product mix moving decisively toward flower. As adult-use pilots […]
Cannabinoids come of age: the clinical-trial pipeline behind Vertanical’s Exilby
Nearly 500 active clinical trials. A 3.5-fold rise in annual trial starts in five years. A decisive pivot away from CBD isolates toward whole-plant, THC-containing medicines aimed at pain. The German authorisation of Vertanical’s Exilby (VER-01) in 2026 — the first high-THC, full-spectrum botanical ever to win pharmaceutical marketing authorisation — is not just a […]
Profitability Arrives as the Access Squeeze Widens — May 2026
Access the full version of this brief with detailed access to the complete recap of the last month, as well as a curated database of market insights and regulation updates. May 2026 sharpened a new imbalance in global cannabis: profitability is finally arriving, while access is tightening at the point of care. In the United […]
UK Medical Cannabis Market Doubles Again — and Flower Loses Share
The UK private medical cannabis market has scaled at a +113% CAGR through 2024. H1 2025 is tracking above 15 tonnes on Q2 run-rate. Behind the headline number, three structural shifts matter: growth rates are decelerating even as volumes still double, product mix is fragmenting beyond flower, and the binding constraints on further scaling are […]
Reform Tracks Diverge as Schedule III Lands — April 2026
Access the full version of this brief with detailed access to the complete recap of the last month, as well as a curated database of market insights and regulation updates. April 2026 saw global cannabis splitting into two reform tracks running in opposite directions. The United States moved medical cannabis to Schedule III, unlocking §280E relief across […]
Global Industry Outpaces Its Regulatory Frameworks — March 2026
Access the full version of this brief with detailed access to the complete recap of the last month, as well as a curated database of market insights and regulation updates. March delivered the clearest evidence yet that the global cannabis industry is maturing faster than the regulatory frameworks governing it. Record earnings seasons in Canada and Germany […]
Canada Ships 276 Tonnes of Medical Cannabis in 2025 — but Growth Signals Are Softening
276 tonnes of medical cannabis flower. C$643 million in export value. Roughly three-quarters of the world’s legal medical supply. Canada’s 2025 export data does not merely extend a growth trend — it redefines the country’s position in the global cannabis trade. In a single year, volumes more than doubled, a single regulatory event in Europe […]
Consolidation Wave Reshapes Global Cannabis — February 2026
Access the full version of this brief with detailed access to the complete recap of over 300 global updates in the last month, as well as a curated database of +7,000 regulation updates, market reports and science papers. February 2026 was defined by cross-border consolidation on an unprecedented scale. Organigram acquired Sanity Group for €227M — Europe’s largest cannabis deal — […]
Germany Imports 201 Tonnes of Medical Cannabis in 2025 and Crosses €1 Billion in Sales
Germany’s pharmacy sell-out market surpassed €1 billion for the first time in 2025, with imports reaching a record 201.1 tonnes (+176% YoY) — making it the largest regulated medical cannabis market globally. This data brief examines the supply chain diversification that accompanied that growth, the regulatory and pricing pressures now reshaping the operator landscape, the […]